Tuesday, June 16, 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer



 CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1      

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China. Binghe Xu, MD, Ph.D., Professor and Director of the Department of Medical Oncology at the Cancer Hospital of Chinese Academy of Medical Sciences is the principal investigator of the trial.


















No comments:

Post a Comment